Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 01:46 | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | SELL | $41.91 | 8,327 | $348,974 | 116,899 |
| 2026-04-16 01:47 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer | OPT+S | $41.29 | 51,500 | $2,126,450 | 105,211 |
| 2026-04-16 01:48 | 2026-04-15 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer | SELL | $41.09 | 64,000 | $2,629,978 | 432,886 |
| 2026-04-16 01:49 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | SELL | $41.93 | 7,215 | $302,516 | 138,608 |
| 2026-04-15 23:59 | 2026-04-13 | WHWK | Whitehawk Therapeutics, Inc. | BALL BRYAN | Officer | SELL | $3.60 | 118,849 | $427,856 | 397,106 |
| 2026-04-15 22:45 | 2026-04-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $66.12 | 7,000 | $462,830 | 33,377 |
| 2026-04-15 22:50 | 2026-04-14 | GNPX | Genprex, Inc. | LONGNECKER BRENT M | Director | SELL | $1.23 | 18 | $22 | 0 |
| 2026-04-15 21:27 | 2026-04-15 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $65.38 | 7,500 | $490,350 | 415,330 |
| 2026-04-15 21:29 | 2026-04-15 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $66.02 | 7,449 | $491,783 | 58,555 |
| 2026-04-15 20:53 | 2026-04-13 | IRON | Disc Medicine, Inc. | Franchi Jean M. | Officer | SELL | $69.23 | 6,657 | $460,834 | 64,333 |
| 2026-04-15 20:57 | 2026-04-14 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer | SELL | $44.05 | 22,951 | $1,011,051 | 235,244 |
| 2026-04-15 21:05 | 2026-04-13 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $66.38 | 5,731 | $380,449 | 79,480 |
| 2026-04-14 21:55 | 2026-04-10 | MLTX | MoonLake Immunotherapeutics | Santos da Silva Jorge | Director, Officer | SELL | $18.35 | 150,000 | $2,752,170 | 2,924,893 |
| 2026-04-14 21:07 | 2026-04-13 | LQDA | Liquidia Corp | Boyle Dana | Officer | OPT+S | $38.37 | 5,101 | $195,725 | 176,918 |
| 2026-04-14 21:07 | 2026-04-13 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $38.37 | 7,301 | $280,139 | 215,426 |
| 2026-04-14 21:08 | 2026-04-13 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $38.34 | 10,547 | $404,402 | 184,558 |
| 2026-04-14 21:05 | 2026-04-10 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | OPT+S | $39.06 | 54,177 | $2,116,262 | 1,495,234 |
| 2026-04-14 21:05 | 2026-04-13 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $38.37 | 13,692 | $525,362 | 610,532 |
| 2026-04-14 21:06 | 2026-04-13 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | OPT+S | $38.37 | 9,220 | $353,771 | 173,270 |
| 2026-04-14 21:06 | 2026-04-13 | LQDA | Liquidia Corp | Krepp Sarah | Officer | OPT+S | $38.37 | 4,557 | $174,852 | 147,019 |
| 2026-04-14 21:07 | 2026-04-10 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $39.36 | 42,779 | $1,683,666 | 405,775 |
| 2026-04-14 20:34 | 2026-04-13 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $574.88 | 10,000 | $5,748,802 | 18,876 |
| 2026-04-14 20:34 | 2026-04-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $574.86 | 9,500 | $5,461,199 | 40,513 |
| 2026-04-14 20:13 | 2026-04-10 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Officer | SELL | $35.03 | 19,865 | $695,823 | 266,651 |
| 2026-04-14 20:16 | 2026-04-10 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $6.20 | 8,000 | $49,600 | 70,405 |
| 2026-04-14 01:13 | 2026-04-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $27.38 | 2,170 | $59,415 | 76,140 |
| 2026-04-14 00:34 | 2026-04-09 | WHWK | Whitehawk Therapeutics, Inc. | BALL BRYAN | Officer | SELL | $3.55 | 56,596 | $201,125 | 515,955 |
| 2026-04-13 22:15 | 2026-04-09 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | SUH, DAVID JR. | Officer | BUY | $5.00 | 200 | $1,000 | 111,866 |
| 2026-04-13 22:06 | 2026-04-09 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $74.61 | 80,000 | $5,968,784 | 4,398,447 |
| 2026-04-13 21:47 | 2026-04-09 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $40.24 | 133,789 | $5,383,388 | 411,855 |
| 2026-04-13 21:47 | 2026-04-09 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | SELL | $40.12 | 25,000 | $1,002,888 | 1,516,667 |
| 2026-04-13 21:20 | 2026-02-18 | ACET | Adicet Bio, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | BUY | $7.17 | 223,596 | $1,603,944 | 1,182,624 |
| 2026-04-13 20:40 | 2026-04-13 | ANIP | ANI PHARMACEUTICALS INC | Cook Meredith | Officer | SELL | $77.95 | 500 | $38,975 | 78,890 |
| 2026-04-13 20:30 | 2026-04-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $104.48 | 3,093 | $323,164 | 65,604 |
| 2026-04-13 20:32 | 2026-04-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $569.28 | 9,500 | $5,408,194 | 40,513 |
| 2026-04-13 20:34 | 2026-04-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | SELL | $46.69 | 1,703 | $79,513 | 12,029 |
| 2026-04-13 20:35 | 2026-04-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | SELL | $46.69 | 6,625 | $309,321 | 27,418 |
| 2026-04-13 20:15 | 2026-04-09 | BLTE | BELITE BIO, INC | Chuang Hao-Yuan | Director, Officer | SELL | $181.50 | 6,200 | $1,125,304 | 93,800 |
| 2026-04-13 20:15 | 2026-04-09 | BLTE | BELITE BIO, INC | Chen Wan-Shan | Director | SELL | $180.43 | 1,100 | $198,473 | 9,096 |
| 2026-04-13 20:15 | 2026-04-09 | BLTE | BELITE BIO, INC | Lin Yu-Hsin | Director, Officer | SELL | $181.45 | 9,200 | $1,669,339 | 170,934 |
| 2026-04-13 20:01 | 2026-04-10 | XNCR | Xencor Inc | Cornelissen Bart Jan | Officer | SELL | $12.29 | 3,499 | $42,990 | 75,898 |
| 2026-04-10 22:46 | 2026-04-09 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | Director, Officer | SELL | $3.38 | 14,500 | $49,010 | 518,622 |
| 2026-04-10 22:00 | 2026-04-08 | ROIV | Roivant Sciences Ltd. | Humes Jennifer | Officer | SELL | $28.37 | 13,538 | $384,073 | 84,191 |
| 2026-04-10 22:06 | 2026-04-09 | MLTX | MoonLake Immunotherapeutics | Bodenstedt Matthias | Officer | SELL | $18.95 | 87,795 | $1,663,935 | 1,188,510 |
| 2026-04-10 21:40 | 2026-04-08 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $311.59 | 332 | $103,448 | 0 |
| 2026-04-10 20:52 | 2026-04-09 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Savitz Ryan | Officer | OPT+S | $89.84 | 8,224 | $738,844 | 0 |
| 2026-04-10 20:32 | 2026-04-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $577.88 | 9,500 | $5,489,819 | 40,513 |
| 2026-04-10 20:33 | 2026-04-09 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $577.89 | 10,000 | $5,778,922 | 18,876 |
| 2026-04-10 20:33 | 2026-04-08 | CRNX | Crinetics Pharmaceuticals, Inc. | Knight Jeff E. | Officer | OPT+S | $40.10 | 85,163 | $3,415,036 | 105,289 |
| 2026-04-10 19:29 | 2026-04-10 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer, 10% owner | BUY | $4.90 | 10,000 | $48,950 | 3,042,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.